Loading…
Nanoviricides Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -69.6% over 5Y.
today you would have $310.34▼ -69.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 20 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.13 | $1.43 | $1.02 | $1.11 | $3.72 | $2.87 | $2.51 | $4.00 | $17.60 | $21.40 | $23.60 | $54.40 | $96.00 | $32.90 | $43.40 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ATNMActinium Pharmaceuticals, Inc. | $1.01 | 2.9x | 1.0x | — | 45.86% | $31.69M |
| SCLXScilex Holding Co | $4.49 | — | — | — | — | $31.59M |
| MIRAMIRA Pharmaceuticals Inc | $0.75 | — | 3.9x | — | -217.12% | $31.52M |
| TELATELA Bio, Inc. | $0.70 |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Company description provided by Yahoo Finance.
| $102.90 |
| $59.50 |
| $56.70 |
| $27.30 |
| $51.80 |
| P/B | 2.4x | 2.6x | 1.8x | 0.8x | 0.6x | 1.4x | — | 0.9x | 0.8x | 2.7x | 2.7x | 2.1x | 6.6x | 30.0x | 5.3x | 8.8x | — | — | — | — | — |
| EPS | -$0.63 | -$0.70 | -$0.74 | -$0.70 | -$0.81 | -$2.39 | -$2.35 | -$2.60 | -$3.40 | -$3.80 | -$1.80 | -$5.40 | -$3.80 | -$3.00 | -$3.20 | -$2.80 | — | — | — | — |
| ROE | -62.74% | -125.93% | -72.35% | -57.77% | -35.12% | -29.49% | -61.80% | -79.47% | -48.48% | -50.71% | -46.53% | -6.92% | -58.20% | -110.81% | -44.82% | -63.68% | -72.78% | -112.16% | -617.11% | -623.37% | -265.20% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $31.43M |
| IGCIGC Pharma, Inc. | $0.31 | — | 5.2x | — | -83.34% | $32.05M |
| CCELCryo Cell International Inc | $4.00 | — | — | 15.00% | — | $32.25M |